Kazia Therapeutics (KZIA) Total Current Liabilities (2009 - 2025)
Kazia Therapeutics (KZIA) posted Total Current Liabilities of $16.0 million for Q4 2025, up 77.81% on a QoQ basis from $9.0 million in Q2 2025, and up 48.2% year-over-year from $10.8 million in Q4 2024.
Kazia Therapeutics (KZIA) has 14 years of Total Current Liabilities data on file, last reported at $16.0 million in Q4 2025.
- In Q4 2025, Total Current Liabilities rose 48.2% year-over-year to $16.0 million; the TTM figure through Dec 2025 stood at $16.0 million (up 48.2% YoY), while the FY2025 annual figure was $9.0 million, down 47.06% from the prior year.
- Total Current Liabilities advanced to $16.0 million in Q4 2025, from $9.0 million in the prior quarter.
- Across five years, Total Current Liabilities topped out at $17.0 million in Q2 2024 and bottomed at $3.7 million in Q4 2022.
- A 5-year average of $8.9 million and a median of $7.4 million in 2023 frame the typical range for Total Current Liabilities.
- Annual changes were most pronounced in 2024 — Total Current Liabilities surged 236.24% — and 2025, when it slumped 47.06%.
- Year by year, Total Current Liabilities stood at $6.4 million in 2021, then tumbled by 42.8% to $3.7 million in 2022, then soared by 101.2% to $7.4 million in 2023, then surged by 46.33% to $10.8 million in 2024, then jumped by 48.2% to $16.0 million in 2025.
- The last three Total Current Liabilities figures came in at $16.0 million (Q4 2025), $9.0 million (Q2 2025), and $10.8 million (Q4 2024), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 16.35 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 1.70 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 636.40 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 66.94 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 13.42 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 3.88 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 5.11 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 1.35 Bn |
| 10 | Kazia Therapeutics | 1.55 Bn | 1.55 Bn | - | 16.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 16.00 Mn |
| Jun 30, 2025 | 9.00 Mn |
| Dec 31, 2024 | 10.80 Mn |
| Jun 30, 2024 | 17.00 Mn |
| Dec 31, 2023 | 7.38 Mn |
| Jun 30, 2023 | 5.06 Mn |
| Dec 31, 2022 | 3.67 Mn |
| Jun 30, 2022 | 4.82 Mn |
| Jun 30, 2021 | 6.41 Mn |
| Dec 31, 2020 | 1.99 Mn |
| Jun 30, 2020 | 3.32 Mn |
| Dec 31, 2019 | 2.11 Mn |
| Jun 30, 2019 | 1.33 Mn |
| Dec 31, 2018 | 1.74 Mn |
| Jun 30, 2018 | 2.94 Mn |
| Jun 30, 2017 | 4.04 Mn |
| Dec 31, 2016 | 5.29 Mn |
| Jun 30, 2016 | 4.02 Mn |
| Jun 30, 2012 | 3.91 Mn |
| Dec 31, 2011 | 5.29 Mn |
| Jun 30, 2011 | 8.71 Mn |
| Dec 31, 2010 | 3.36 Mn |
| Jun 30, 2010 | 5.27 Mn |
| Dec 31, 2009 | 3.05 Mn |
| Jun 30, 2009 | 6.70 Mn |